Role of CHI3L1 in accelerating breast cancer metastasis

CHI3L1在加速乳腺癌转移中的作用

基本信息

项目摘要

Metastasis is responsible for a majority of breast cancer deaths. Recent studies estimate that rate of recurrent metastasis of breast cancer is twice as high in patients with asthma compared to those without asthma. High levels of CHI3L1 are found in asthma and breast cancer with even higher levels when these diseases are present together. We hypothesize that CHI3L1- induced pulmonary inflammation generates the proper environment for recruiting circulating breast cancer cells, thus increasing the rate of metastasis to the lung. Thus, inhibiting CHI3L1 is expected to reduce metastasis. We have recently shown that chitin microparticles, the biological binding partner for CHI3L1 decrease pulmonary metastasis and increase survival in mammary tumor-bearing mice. We propose the following two specific Aims: 1) To determine if inflammation associated with CHI3L1 in the lung alters the pulmonary environment to attract circulating breast tumor cells and accelerate metastatic growth and 2) To determine if inhibition of CHI3L1 by either chitin microparticles, anti-CHI3L1 neutralizing antibody or combination of the two decreases tumor metastasis. These Aims will be addressed by inducing pulmonary inflammation by either ragweed allergen sensitization or by locally expressing CHI3L1 in the lung using AAV-CHI3L1 vector. We will then determine the changes in pulmonary tissue and if it provides the necessary "soil" for the circulating breast tumor cells. Towards this goal, in vivo imaging for tumor growth and metastasis and related inflammatory response will be determined. We will also determine if inhibition of CHI3L1 significantly reduces tumor growth and metastasis. Significance: Asthma and pulmonary diseases are characterized by increased expression of CHI3L1. Rates of pulmonary inflammation due to pollution, allergies and smoking have been steadily increasing. The studies proposed here will provide a greater understanding of the role of CHI3L1 in enhancing metastasis and the tissue-specific molecular signals that act to exacerbate metastasis under conditions of chronic inflammation. Moreover limiting inflammation by use of molecules that block the activity of CHI3L1 in vivo has the potential to decrease metastasis for many cancer patients also suffering from inflammatory diseases. Combining immunotherapy (anti-CHI3L1 antibody) with the natural bio-product chitin particles could provide novel modes of treatment options for inhibiting metastatic diseases.
转移是导致大多数乳腺癌死亡的原因。最近的研究估计,哮喘患者的乳腺癌复发转移率是无哮喘患者的两倍。在哮喘和乳腺癌中发现高水平的CHI3L1,当这些疾病同时出现时,其水平甚至更高。我们假设CHI3L1诱导的肺部炎症为招募循环乳腺癌细胞提供了适当的环境,从而增加了转移到肺部的率。因此,抑制CHI3L1有望减少转移。我们最近的研究表明,CHI3L1的生物结合伙伴几丁质微粒可以减少乳腺荷瘤小鼠的肺转移并提高生存率。我们提出以下两个具体目的:1)确定肺中与CHI3L1相关的炎症是否改变肺部环境以吸引循环乳腺肿瘤细胞并加速转移生长;2)确定几丁质微粒、抗CHI3L1中和抗体或两者联合抑制CHI3L1是否会减少肿瘤转移。这些目的将通过豚草过敏原致敏诱导肺部炎症或使用AAV-CHI3L1载体在肺中局部表达CHI3L1来解决。然后我们将确定肺组织的变化,以及它是否为循环乳腺肿瘤细胞提供了必要的“土壤”。为了实现这一目标,将确定肿瘤生长和转移的体内成像以及相关的炎症反应。我们还将确定抑制CHI3L1是否能显著减少肿瘤的生长和转移。意义:哮喘和肺部疾病以CHI3L1表达增高为特征。由污染、过敏和吸烟引起的肺部炎症的发病率一直在稳步上升。本文提出的研究将进一步了解CHI3L1在促进转移中的作用,以及慢性炎症条件下加剧转移的组织特异性分子信号。此外,通过在体内使用阻断CHI3L1活性的分子来限制炎症有可能减少许多患有炎症性疾病的癌症患者的转移。将免疫疗法(抗chi3l1抗体)与天然生物制品甲壳素颗粒相结合,可以为抑制转移性疾病提供新的治疗选择。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Semaphorin7A: branching beyond axonal guidance and into immunity.
  • DOI:
    10.1007/s12026-013-8460-5
  • 发表时间:
    2013-12
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Garcia-Areas, Ramon;Libreros, Stephania;Iragavarapu-Charyulu, Vijaya
  • 通讯作者:
    Iragavarapu-Charyulu, Vijaya
Exploring the role of CHI3L1 in "pre-metastatic" lungs of mammary tumor-bearing mice.
  • DOI:
    10.3389/fphys.2013.00392
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Libreros S;Garcia-Areas R;Keating P;Carrio R;Iragavarapu-Charyulu VL
  • 通讯作者:
    Iragavarapu-Charyulu VL
Semaphorin7A promotes tumor growth and exerts a pro-angiogenic effect in macrophages of mammary tumor-bearing mice.
  • DOI:
    10.3389/fphys.2014.00017
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Garcia-Areas R;Libreros S;Amat S;Keating P;Carrio R;Robinson P;Blieden C;Iragavarapu-Charyulu V
  • 通讯作者:
    Iragavarapu-Charyulu V
CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors.
  • DOI:
    10.1007/s12026-013-8459-y
  • 发表时间:
    2013-12
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Libreros, Stephania;Garcia-Areas, Ramon;Iragavarapu-Charyulu, Vijaya
  • 通讯作者:
    Iragavarapu-Charyulu, Vijaya
Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model.
  • DOI:
    10.1002/ijc.26379
  • 发表时间:
    2012-07-15
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Libreros, Stephania;Garcia-Areas, Ramon;Shibata, Yoshimi;Carrio, Roberto;Torroella-Kouri, Marta;Iragavarapu-Charyulu, Vijaya
  • 通讯作者:
    Iragavarapu-Charyulu, Vijaya
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

VIJAYA L IRAGAVARAPU-CHARYULU其他文献

VIJAYA L IRAGAVARAPU-CHARYULU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('VIJAYA L IRAGAVARAPU-CHARYULU', 18)}}的其他基金

Interfering with CCL2 and CCR2 to limit tumor growth
干扰 CCL2 和 CCR2 以限制肿瘤生长
  • 批准号:
    7914760
  • 财政年份:
    2009
  • 资助金额:
    $ 9.68万
  • 项目类别:
Role of CHI3L1 in accelerating breast cancer metastasis: a mechanistic approach
CHI3L1 在加速乳腺癌转移中的作用:一种机制方法
  • 批准号:
    8367383
  • 财政年份:
    2008
  • 资助金额:
    $ 9.68万
  • 项目类别:
Interfering with CCL2 and CCR2 to limit tumor growth
干扰 CCL2 和 CCR2 以限制肿瘤生长
  • 批准号:
    7516479
  • 财政年份:
    2008
  • 资助金额:
    $ 9.68万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 9.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 9.68万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 9.68万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 9.68万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 9.68万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 9.68万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 9.68万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 9.68万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 9.68万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 9.68万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了